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We investigated inaugural disease phenotype in relation to the presence or absence of diabetes-associated 
autoantibodies and human leukocyte antigen (HLA) DQ risk genotypes in adult-onset diabetic patients. Blood 
samples and questionnaires were obtained from 1584 recent-onset Belgian Caucasian patients (age 15-39 yr at 
diagnosis of primary diabetes) who were recruited by the Belgian Diabetes Registry over an 11-yr period. At 
clinical diagnosis, antibody-positive patients (n = 1198) were on average younger and had more symptoms, a 
more acute disease onset, lower body mass index, and random C-peptide levels, but higher insulin needs, 
glycemia, and prevalence of ketonuria, HLA-DQ, and 5' insulin gene susceptibility genotypes (P < 0.001 vs. 
antibody-negative patients; n = 386). In antibody-positive patients, these characteristics did not differ according 
to HLA-DQ genotype. However, in antibody-negative subjects, we found that patients were younger (P = 
0.001); had a lower body mass index (P < 0.001), higher insulin needs (P = 0.014), and amylasemia (P = 
0.001); and tended to have a higher glycemia and lower C-peptide in the presence of susceptible HLA-DQ 
genotypes. Differences according to HLA-DQ genotype subsisted after careful age-matching. In conclusion, we 
found no relation between initial disease phenotype and HLA-DQ genotype in antibody-positive diabetic young 
adults. In contrast, antibody-negative patients displayed more type 1-like features when carrying susceptible 
HLA-DQ genotypes known to promote the development of antibody-positive diabetes. The overrepresenta- tion 
of these susceptibility genotypes in antibody-negative patients suggests the existence of an immune-mediated 
disease process with as yet unidentified immune markers in a subgroup of seronegative patients. ( J Clin 
Endocrinol Metab 87: 2597-2605, 2002) 
MOST CASES OF type 1 diabetes are believed to arise from the nearly complete destruction of insulin-
producing β-cells by immune effector cells [1] . Although there are indications that the underlying pathological 
process is often initiated in early childhood, the disease can become clinically manifest at any age, most cases 
arising after age 15 yr [1] [2] [3] [4] [5]. The disease presents along a clinical spectrum ranging from acute-onset 
ketosis-prone diabetes to latent forms with slow progression to insulin deficiency after initial manifestation [6][7][8] 
[9]. Disease phenotype, underlying pathologic changes, and associated biological markers tend to change with age 
at diagnosis [3] [9] [10] [11] [12] [13] [14] [15]. Overall, it becomes increasingly difficult to clinically distinguish type 1 
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diabetes from other forms of the disease with older age at clinical manifestation[3] [4] [6] [9] . There is thus a need 
for additional biological markers of adult-onset type 1 diabetes. 
The American Diabetes Association and the World Health Organization recently proposed new classification 
criteria for diabetes in which the presence or absence of diabetes-associated autoantibodies plays a central role 
[7][8]. Immunemediated type 1 diabetes (type 1A) is defined as hyperglycemia in the presence of autoantibodies 
against β-cell antigens [7][8]. These patients preferentially carry specific HLA-DQA1-DQB1 risk haplotypes 
(0301-0302 and/or 0501-0201) [7][8] . In initially noninsulin-requiring adult-onset patients, the presence of 
autoantibodies has been associated with lower body mass index (BMI), less preserved residual β-cell mass, and 
more rapid evolution toward insulin dependency [6][16][17]. However, a number of diabetic patients, mostly of 
African or Asian origin, presents with variable degrees of insulin deficiency in the absence of circulating 
diabetes autoantibodies [7][8]. A recent Japanese study reported a subgroup of diabetic patients with abrupt 
clinical onset of diabetes in adulthood without detectable insulitis or diabetes-associated autoantibodies, but 
characterized by the presence of hyperamylasemia, hyperlipasemia, and lymphocytic infiltration of the exocrine 
pancreas [19]. Whether this subtype occurs in Caucasian populations has so far not been confirmed [20] [21]. The 
absence of autoantibodies at diagnosis does, however, not exclude the existence of an immunemediated β-cell 
destruction because we and others have occasionally observed the appearance of diabetes-associated 
autoantibodies after clinical onset[22] [23]. Likewise, it is conceivable that some patients may have lost 
autoantibodies before diagnosis or present other immune markers than those currently searched for[23] . To 
further improve the etiological classification of adult-onset diabetes, and hence etiology-based therapeutic 
schemes, it is important to try to relate clinical disease phenotype to biological markers of immune-mediated 
diabetes also in the absence of autoantibodies. 
Therefore, the aims of the present report were: 1) to study the clinical phenotype of adult-onset diabetic patients 
after stratification for diabetes-associated autoantibodies, and 2) to investigate the possible interaction between 
the disease phenotype and HLA-DQ genotype in a representative population of adult-onset diabetic patients 
stratified according to the presence or absence of autoantibodies. 
Figure 1. Number of included diabetic patients aged 15-39 yr, according to antibody status and HLA-DQ 
genotype.a Absence of gestational or secondary diabetes; Caucasian ethnicity; availability of demographic data 
and blood samples for DNA, autoantibody, and chemical analysis within 18 months after diagnosis; and Belgian 
residency for at least 6 months before diagnosis.b From 1488 of 1584 included patients (94%), a standard 
questionnaire was available with epidemiological, clinical, and locally determined biological data.c Positivity 
for ICA, GADA, and/or IA-2A; negativity for ICA, GAD A, and IA-2A. d For the definition of HLA-DQ 
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SUBJECTS AND METHODS  
Subjects 
Between January 1989 and December 1999, 1721 patients (age 15-39 yr) were consecutively recruited by the 
Belgian Diabetes Registry (BDR), a national data and sample bank for recent-onset diabetic patients and their 
first-degree relatives under age 40 [3]. Registration of newly diagnosed diabetic patients (all types of diabetes) 
into the BDR is based on the voluntary reporting by pediatricians and endocrinologists participating in the BDR. 
Diabetes was diagnosed according to the criteria of the National Diabetes Data Group [24]. Comparison with a 
subregion (Antwerp district) with nearly complete case ascertainment (94%) has demonstrated that the larger 
Belgian group of patients, with incomplete ascertainment (presently 55%), is representative for the Belgian 
diabetic patients with diagnosis before age 40 yr[25]. Of the 1721 patients, 1584 were included after verification 
of the following criteria: 1) absence of gestational or secondary diabetes; 2) Caucasian ethnicity; 3) availability 
of demographic data and samples for DNA, autoantibody, and chemical analysis taken within the first 18 months 
after diagnosis; and 4) Belgian residency for at least 6 months before diagnosis ( Fig. 1 ). From 1488 included 
patients (94%), a standard questionnaire with epidemiological, clinical, demographic, and local biological data 
was available. Patients (n = 1584) were stratified according to the presence (immune-mediated type 1 diabetic 
patients) or absence (patients without evidence of immune-mediated type 1 diabetes) of autoantibodies at 
diagnosis or during follow-up [7] [8]. A total of 1198 subjects (76%) showed positivity for at least one type of 
autoantibody [islet cell cytoplasmic antibodies (ICA), glutamate decarboxylase antibodies (GADA), or 
insulinoma-associated antigen 2 antibodies (IA-2A)] at first sampling and/or in any later available blood sample 
( Fig. 1). Because patients could be included until 18 months after diagnosis, insulin antibodies were not 
considered in this analysis. It has, moreover, been shown that less than 1% of the diabetic patients diagnosed in 
young adulthood are positive for insulin autoantibodies (IAA) at clinical onset in the absence of ICA and GADA 
[26] . Additional stratification was performed according to the presence or absence of HLA-DQ susceptibility 
genotypes (Fig. 1). At diagnosis, patients were tentatively classified as type 1, type 2, or unclassifiable diabetes 
by their treating physicians who were unaware of the antibody or HLA-DQ status at that time. 
The study was approved by the ethical committee of the BDR and the universities participating in its scientific 
projects. Informed consent was obtained from each subject and from the parents in case of minors in accordance 
with the Helsinki Declaration. 
Antibody assays 
ICA were measured with an indirect immunofluorescence assay using cryosections of fresh-frozen human blood 
group O pancreas for substrate[11]. The results were expressed in Juvenile Diabetes Foundation (JDF) units. 
Autoantibodies against GADA and IA-2A were determined by liquid phase radio-binding assay using 
recombinant human 35 S-labeled intact glutamate decarboxylase (65 kDa isoform) and the 35 S-labeled 
intracellular domain of insulinoma-associated antigen 2 for tracer, respectively [27]. Cut-off values for positivity 
for ICA (>12 JDF units), GADA (>2.6% tracer bound), and IA-2A (>0.4% tracer bound) were established to 
secure 99% diagnostic specificity after omission of outlying values based on the analysis of 789 healthy control 
subjects [23]. The antibody assays performed repeatedly well in successive external quality control programs 
(Immunology of Diabetes Workshops, Proficiency Testing of the University of Florida, Gainesville, FL, and of 
the Research Institute for Children, New Orleans, LA). In the latter program, our three assays achieved 100% 
diagnostic sensitivity, specificity, consistency, and validity. In the combinatorial islet autoantibody workshop 
assay, sensitivity adjusted for 99% specificity amounted to 73% for ICA and 85% for GADA (IA-2A was not yet 
available in our laboratory at the time of the workshop, i.e. 1995) [28] . 
Genetic analysis 
DNA was extracted from 5 ml potassium EDTA-blood by proteinase-K digestion of SDS-treated white blood 
cells and subsequent phenol extraction or salt precipitation. The second exons of the DQA1 and DQB1 alleles 
were simultaneously amplified by PCR using primer sets that were described previously [29]. Amplified DNA 
was dot-blotted on nylon membranes, fixed by UV irradiation, and hybridized to a panel of 15 different 
digoxigenin-deoxyuridine triphosphate-labeled allele-specific oligonucleotide probes. After posthybridization 
washings, the membranes were incubated with antidigoxigenin antibody conjugated to alkaline phosphatase, and 
probe signals were visualized by chemiluminescent detection [30]. 
On the basis of the comparison of HLA-DQA1-DQB1 genotypes in 1866 antibody-positive recent-onset diabetic 
patients aged under 40 yr at diagnosis (recruited in Belgium between January 1989 and March 1999) and 750 
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nondiabetic Belgian residents, the following genotypes were found to confer significant susceptibility for type 1 
diabetes in the Belgian population [31] : DQA1*0501-DQB1*0201/DQA1*0301-DQB 1*0302 [odds ratio (OR), 
21.3; 95% confidence interval (CI), 12.2-38.0], homozygosity for DQA1*0301-DQB1*0302 (OR, 8.2; 95% CI, 
3.2-22.8), or DQA1*0501DQB1*0201 (OR, 5.0; 95% CI, 2.8-8.8) and DQA1*0301-DQB1*0302 in combination 
with one of the neutral DQA1*-DQB1* haplotypes (0100-0501/0604/0605, 0102-0201, 0102-0502, 0301-0201, 
0301-0301, 0301-0303, 0301-0401, 0401-0402 or 0501-0302) (OR, 4.3; 95% CI, 3.0-6.4). Overall, in subjects 
carrying one of the above susceptibility genotypes, the OR (95% CI) for type 1 diabetes amounted to 15.3 (11.6- 
20.1)[31]. 
The variable number of tandem repeats polymorphism upstream from the insulin gene (INS) transcription 
initiation site (5INS) was detected by assessment of a diallelic adenine/thymidine polymorphism at position -23 
of the INS gene which is in nearly complete linkage disequilibrium with the 5'INS variable number of tandem 
repeats. Genotypes were assessed by conventional PCR restriction fragment length polymorphism analysis with 
restriction enzyme HphI (Amersham Pharmacia Biotech, Uppsala, Sweden)[31] or by a 5'nuclease (TaqMan) 
assay with fluorogenic probes [30] on the ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems, 
Foster City, CA). 
Other biological markers 
Random C-peptide levels were determined on the serum samples collected for the analysis of diabetes-associated 
autoantibodies. The C-peptide assay was performed with a commercial kit (125I-human Cpeptide, guinea pig 
antihuman C-peptide serum; Linco Research Inc., St. Charles, MO) that has its lower detection limit at 20 
pmol/liter[33]. The same serum samples were analyzed for glucose and total activities of amylase and lipase using 
a Vitros 950 IC analyser and dedicated Vitros slides (Ortho Clinical Diagnostics, Rochester, NY) according to 
the manufacturer's specifications [34]. 
Statistical analysis 
Differences between groups were assessed by Mann-Whitney U test for continuous variables and by χ2 test with 
Yates' correction or Fisher's exact test, whenever appropriate, for categorical variables. Multivariate analysis was 
performed by forward stepwise logistic regression with the genotype as the dependent variable and age, BMI, 
amylase activity, and random C-peptide levels as independent variables. C-peptide was log-transformed before 
multivariate analysis. All statistical tests were performed two-tailed by SPSS for Windows 10.0 (SPSS, Inc., 
Chicago, IL) for personal computers and were considered significant at P value less than 0.05 or, in case of k 
independent tests, at P value less than 0.05/ k (Bonferroni correction) [35]. 
TABLE 1 — Demographic and clinical characteristics of 1584 diabetic patients (all phenotypes) aged 15-39 yr at diagnosis 
Characteristics Antibody-positive 
patients (n = 1198) 
Antibody-negative 
patients (n = 386) 
P valuea
Age at diagnosis (yr)b 26 (20-31) 32 (26-36) <0.001 
Male-to-female ratio [no. of patients (ratio)] 717/481 (1.49) 259/127 (2.04) 0.013 
Presence of one or more symptomsc [no. of patients 
(%)] 
1099/1140 (96) 306/347 (88) <0.001 
Duration of symptomsd (wk)b 4 (2-8) 6 (2-12) <0.001 
BMIe(kg/m2)b 21 (19-23) 25 (22-30) <0.001 
Daily insulin dose after stabilizationf(U/kg)b 0.47 (0.31-0.67) 0.34 (0.10-0.53) <0.001 
Initial classification as type 1 by treating physician [no. 
of patients (%)] 
1139/1198 (95) 237/386 (61) <0.001 
a Mann-Whitney U test was used for continuous variables and χ2 test for categorical variables; the threshold for statistical significance is P < 
0.05/7 or P < 0.007 (Bonferroni adjustment). 
b Median (interquartile range). 
c Polyuria, polydipsia, weight loss, and/or fatigue. 
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d Data were available for 963 antibody -positive and 302 antibody -negative patients. 
e Data were available for 1036 antibody -positive and 327 antibody -negative patients. 
f Data were available for 877 antibody -positive and 298 antibody -negative patients. 
RESULTS 
Clinical and biological characteristics according to autoantibody status 
At diagnosis, antibody -positive patients (n = 1198) differed significantly in terms of clinical presentation and 
biological characteristics from antibody-negative patients (n = 386) ( Fig. 1 ). Overall, antibody -positive 
subjects were younger (26 vs. 32 yr; P < 0.001), and they more frequently presented clinical symptoms of 
diabetes such as polyuria, polydipsia, fatigue, or weight loss (96 vs. 88%; P < 0.001) with an overall shorter 
duration of the prodromal phase (4 vs. 6 wk; P < 0.001); they were leaner at diagnosis (BMI, 21 vs. 25 kg/m2 ; P 
< 0.001), had higher insulin requirements after stabilization (0.47 vs. 0.34 U/kg·d; P < 0.001), and were initially 
more often classified as type 1 patients by their treating physician (95 vs. 61%; P < 0.001) (Table 1). At 
diagnosis, 96% of the antibody-positive patients were treated with insulin, compared with 76% of the antibody-
negative patients (P < 0.001). The reported male-to-female excess[14] tended to be more pronounced in the 
absence of antibodies (Table 1). 
Compared with antibody-negative patients, antibody-positive subjects showed lower random C-peptide values 
(0.62 vs. 1.39 µg/liter; P < 0.001), despite higher random glycemia levels (350 vs. 294 mg/dl; P < 0.001), and 
had a higher prevalence of ketonuria (74 vs. 47%; P < 0.001), HLA-DQ (57 vs. 21%), and 5'INS (70 vs. 54%) 
risk markers (P < 0.001) (Table 2). The prevalence of susceptible HLA-DQ genotypes, but not of 5'INS I/I, was 
higher in antibody-negative patients than in control subjects (21 vs. 9%, P < 0.001; and 54 vs. 47%, P > 0.05, 
respectively) (Table 2). Both the high-risk heterozygous HLA-DQ genotype 0301-0302/0501-0201 and the 
presence of two susceptibility haplotypes (0301-0302 and/or 0501-0201 in homozygous or heterozygous 
combination) were significantly more prevalent in antibody -negative patients than in nondiabetic control 
subjects (7.5 vs. 1.9%, P < 0.001; and 14.8 vs. 4.5%, P < 0.001, respectively). Glycosylated hemoglobin (HbAlc) 
levels tended to be higher in the presence of autoantibodies (P = 0.038) (Table 2). Serum amylase and lipase 
activities did not differ according to antibody status (Table 2). During follow-up [mean (range), 25 (2-60) 
months], antibody-positive subjects (n = 677) persistently showed lower BMI, higher insulin requirements, and 
lower random C-peptide levels than antibody-negative patients (n = 149; P < 0.001; data not shown). Also 
during follow-up, antibody-positive patients were more frequently treated with insulin (98 vs. 81%; P < 0.001). 
Regardless of HLA-DQ status, the presence of first-degree relatives with type 1 and/or type 2 diabetes was more 
frequently reported in antibody-negative patients than in antibody-positive subjects (34 vs. 20%; P < 0.001). 
TABLE 2 — Biological characteristics of 1584 diabetic patients aged 15-39 yr at diagnosis 
Characteristics Antibody-positive 
patients (n = 1198) 
Antibody-negative 
patients (n = 386) 
P valuea
Ketonuria [no. of patients (%)] 678/911 (74) 130/276 (47) <0.001 
Random glycemiac (mg/dl)b 350 (271-469) 294 (207-371) <0.001 
HbAlc d— SD from mean of local reference intervalb 10.4 (6.9-14.5) 9.7 (5.4-14.8) 0.038 
Random C-peptidee(µg/liter)b 0.62 (0.35-1.04) 1.39 (0.80-2.36) <0.001 
HLA DQA1 *-DQB 1 * genotype    
Protective/neutral 519/1198(43) 304/386 (79) <0.001 
Susceptible 679/1198(57) 82/386 (21)  
5'INS I/I genotype 782/1111 (70) 193/357 (54) <0.001 
Amylasef(U/liter)b 47 (39-56) 46 (38-55) 0.172 
Lipasef(U/liter)b 73 (44-116) 68 (38-113) 0.160 
a Mann-Whitney U test was used for continuous variables and χ2 test for categorical variables; the threshold for statistical significance is P < 
0.05/8 or P < 0.006 (Bonferroni adjustment). 
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c Data were available for 1109 antibody-positive and 346 antibody-negative patients. 
b Median (interquartile range). 
d Data were available for 1019 antibody-positive and 326 antibody-negative patients. 
e Data were available for 1041 antibody-positive and 381 antibody-negative patients. 
f Data were available for 1028 antibody-positive and 377 antibody-negative patients. 
 
TABLE 3 — Demographic and clinical characteristics of 1198 antibody -positive diabetic patients aged 15-39 yr according 
to HLA-DQ genotype 
Characteristics HLA-DQ genotype P valuea
 
 
Susceptible (n = 
679) 




Age at diagnosis (yr)b 25 (20-31) 27 (20-32) 0.098 
Male-to-female ratio [no. of patients (ratio)] 388/291 (1.33) 329/190 (1.73) 0.033 
Presence of one or more symptomsc [no. of 
patients (%)] 
625/646 (97) 474/494 (96) 0.578 
Duration of symptoms d(wk)b 4 (2-8) 4 (2-8) 0.992 
BMIe (kg/m2)b 21 (19-23) 21 (19-24) 0.199 
Daily insulin dose after stabilizationf(U/kg)b 0.48 (0.32-0.67) 0.46 (0.31-0.68) 0.875 
Initial classification as type 1 by treating physician [no. of 
patients (%)] 
647/679 (95) 492/519 (95) 0.800 
a Mann-Whitney U test was used for continuous variables and χ2 test for categorical variables; the threshold for statistical significance is P < 
0.05/7 or P < 0.007 (Bonferroni adjustment). 
b Median (interquartile range). 
c Polyuria, polydipsia, weight loss, and/or fatigue. 
d Data were available for 546 patients with susceptible and 417 patients with protective/neutral genotypes. 
e Data were available for 592 patients with susceptible and 444 patients with protective/neutral genotypes. 
f Data were available for 504 patients with susceptible and 373 patients with protective/neutral genotypes. 
 
CLINICAL AND BIOLOGICAL CHARACTERISTICS ACCORDING TO HLADQ GENOTYPE 
Antibody-positive patients. 
There were no significant differences in clinical (Table 3) or biological (Table 4) characteristics according to 
HLA-DQ genotype in antibody-positive subjects, except for a trend toward older age at onset (P = 0.098) (Table 
3) and higher male-to-female ratio (P = 0.033) (Table 3), random glycemia (P = 0.022), HbAlc levels (P = 
0.046), and prevalence of the 5'INS I/I genotype (P = 0.038) (Table 4) in the absence of HLA-DQ susceptibility 
genotypes. Furthermore, during follow-up, we found no differences in functional residual β-cell mass, frequency 
of insulin treatment, or insulin needs for similar glycemic control after stratification for HLA-DQ risk 
(susceptible, n = 380; protective/neutral, n = 297; data not shown). 
Antibody-negative patients. 
In contrast to antibody -positive subjects, antibody -negative patients did markedly differ in terms of clinical 
presentation and biological markers at diagnosis according to the presence or absence of susceptible HLA-DQ 
genotypes. Subjects carrying susceptible genotypes were overall younger (28 vs. 33 yr; P = 0.001), had a lower 
BMI (23 vs. 26 kg/m2 ; P < 0.001), and tended to have higher insulin requirements after stabilization (0.41 vs. 
0.32 U/kg·d; P = 0.014) (Table 5) to achieve the same degree of glycemic equilibration as reflected by similar 
HbAlc levels (Table 6). These patients were significantly more often classified as suffering from type 1 diabetes 
by their treating physician compared with subjects carrying protective or neutral HLA-DQ genotypes (78% vs. 
57%; P = 0.001) (Table 5). There was a tendency toward lower random C-peptide values (1.13 vs. 1.51 µg/liter; 
P = 0.034) in subjects with susceptible genotypes (Table 6). Amylase activity, but not lipase activity, was overall 
higher (P = 0.001) in subjects with the susceptible genotypes. However, this was not reflected in a higher 
prevalence of amylase activity above the upper limit of reference values (cut off, 113 U/liter). 
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TABLE 4 — Biological characteristics of 1198 antibody-positive diabetic patients aged 15-39 yr according to HLA-DQ 
genotype 
Characteristics HLA-DQ genotype P valuea
 
 
Susceptible (n = 
679) 




Ketonuria [no. of patients (%)] 380/514 (74) 298/397 (75) 0.755 
Random glycemiac (mg/dl)b 343 (270-450) 364 (277-499) 0.022 
HbAlc d( SD from mean of local reference interval)b 10.0 (6.9-14.2) 10.9 (7.0-15.4) 0.046 
Random C-peptidee(µg/liter)b 0.62 (0.37-1.02) 0.61 (0.34-1.06) 0.938 
5'INS I/I genotype [no. of patients (%)] 428/631 (68) 354/480 (74) 0.038 
Amylasef (U/liter)b 47 (39-56) 47 (39-56) 0.780 
Lipasef (U/liter)b 73 (43-114) 76 (46-116) 0.192 
α Mann-Whitney U test was used for continuous variables and χ2 test for categorical variables; the threshold for statistical significance is P < 
0.05/7 or P < 0.007 (Bonferroni adjustment). 
c Data were available for 635 patients with susceptible and 474 patients with protective/neutral genotypes. 
b Median (interquartile range). 
d Data were available for 584 patients with susceptible and 435 patients with protective/neutral genotypes. 
e Data were available for 586 patients with susceptible and 455 patients with protective/neutral genotypes. 
f Data were available for 578 patients with susceptible and 450 patients with protective/neutral genotypes. 
TABLE 5 — Demographic and clinical characteristics of 386 autoantibody -negative diabetic patients aged 15-39 yr 
according to HLA-DQ genotype 
HLA-DQ genotype Characteristics 
Susceptible (n = 82) Protective/neutral (n = 
304) 
P 
Age at diagnosis (yr)b 28 (22-35) 33 (27-36) 0.001 
Male-to-female ratio [no. of patients (ratio)] 57/25 (2.28) 202/102 (1.98) 0.695 
Presence of one or more symptomsc [no. of patients (%)] 65/74 (88) 241/273 (88) 1.000 
Duration of symptoms d (wk)b 4 (2-9) 6 (2-16) 0.147 
BMIe(kg/m2)b 23 (20-27) 26 (22-30) <0.001 
Daily insulin dose after stabilizationf(U/kg)b 0.41 (0.21-0.66) 0.32 (0.00-0.50) 0.014 
Initial classification as type 1 by treating physician [no. of 
patients (%)] 
64/82 (78) 173/304 (57) 0.001 
a Mann-Whitney U test was used for continuous variables and χ2 test for categorical variables; the threshold for 
statistical significance is P < 0.05/7 or P < 0.007 (Bonferroni adjustment). 
b Median (interquartile range). 
c Polyuria, polydipsia, weight loss, and/or fatigue. 
d Data were available for 65 patients with susceptible and 237 patients with protective/neutral genotypes. 
e Data were available for 67 patients with susceptible and 260 patients with protective/neutral genotypes. 
f Data were available for 58 patients with susceptible and 240 patients with protective/neutral genotypes. 
Stepwise forward logistic regression analysis confirmed that in antibody-negative patients with onset in young 
adulthood, the presence of HLA-DQ susceptibility genes is associated with younger age at diagnosis (P = 0.014; 
OR, 1.052; 95% CI, 1.010-1.095) and independently of age also with BMI (P = 0.017; OR, 1.071; 95% CI, 
1.013-1.133) and amylase activity (P = 0.051; OR, 0.983; 95% CI, 0.967-1.000). Likewise, when all 82 antibody 
-negative patients with HLA-DQ susceptibility genotypes were one by one matched to an antibody-negative 
patient of exactly the same age carrying a neutral or protective HLA-DQ genotype, thereby dissipating the age 
difference between both groups (median age, 28 yr; interquartile range, 22-35 yr, in both groups), the trend 
toward lower BMI (23 vs. 25 kg/m2 ; P = 0.026), more frequent classification as type 1 diabetes (78 vs. 60%; P 
= 0.018), lower random C-peptide values (1.12 vs. 1.65 µg/liter; P = 0.009), and higher amylase activity (50 vs. 
47 U/liter; P = 0.05) in the presence of HLA-DQ susceptibility genotypes persisted (Table 7). Furthermore, after 
a median follow-up of 25 months (range, 20-60 months), antibody -negative patients still presented a lower BMI 
(P = 0.001) and tended to have higher insulin needs (P = 0.073) to achieve similar glycemic control in the 
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presence of HLA-DQ risk genotypes (n = 29) than in their absence (n = 120; data not shown). Neither at 
diagnosis nor after follow-up was there a significant difference in the frequency of insulin treatment between 
patients with or without HLA-DQ risk genotypes. 
CLINICAL AND BIOLOGICAL CHARACTERISTICS ACCORDING TO OTHER VARIABLES 
Antibody-negative patients with HbAlc values above percentile 50 (i.e. HbAlc ≥ 10.3 SD above mean of local 
reference interval) presented symptoms more frequently (P = 0.004) and had a higher prevalence of ketonuria (P 
< 0.001), higher insulin requirements (P< 0.001), higher glycemia at diagnosis (P < 0.001), and lower random 
C-peptide levels (P < 0.001) compared with antibody-negative patients with HbAlc values below percentile 50 
(data not shown). Similar findings were observed in antibody-positive patients (data not shown) or when 
comparing patients with HbAlc below percentile 33 and above percentile 66 (data not shown). Regardless of 
antibody and HLA-DQ status, there was no difference in the prevalence of the 5'INS I/I risk genotype according 
to BMI (patients with BMI > percentile 50 vs. BMI < percentile 50, or patients with BMI > percentile 66 vs. BMI 
< percentile 33) or in BMI according to 5'INS status (data not shown). 
TABLE 6 — Biological characteristics of 386 autoantibody-negative diabetic patients aged 15-39 yr according to HLA-DQ 
genotype 
HLA-DQ genotype Characteristics 
 




Ketonuria [no. of patients (%)] 33/64 (52) 97/212 (46) 0.501 
Random glycemiac(mg/dl)b 309 (207-415) 291 (207-365) 0.130 
HbAlc d ( SD from mean of local reference 
interval)b
8.6 (4.4-14.7) 9.7 (5.4-14.8) 0.651 
Random C-peptidee(µg/liter) 1.13 (0.59-2.11) 1.51 (0.88-2.38) 0.034 
5'INS I/I genotype [no. of patients (%)] 46/76 (61) 147/281 (52) 0.252 
Amylasef(U/liter)b 50 (44-57) 44 (37-54) 0.001 
Lipasef(U/liter)b 70 (38-113) 67 (37-114) 0.627 
a Mann-Whitney U test was used for continuous variables and χ2 test for categorical variables; the threshold for statistical significance is P < 
0.05/7 or P < 0.007 (Bonferroni adjustment). 
c Data were available for 71 patients with susceptible and 275 patients with protective/neutral genotypes. 
b Median (interquartile range). 
d Data were available for 67 patients with susceptible and 259 patients with protective/neutral genotypes. 
e Data were available for 81 patients with susceptible and 300 patients with protective/neutral genotypes. 
f  Data were available for 80 patients with susceptible and 297 patients with protective/neutral genotypes. 
 
 
TABLE 7 — Clinical and biological characteristics of 164 age-matched autoantibody-negative diabetic patients aged 15-39 




(n = 82) (n = 82) 
P 
 
BMIc (kg/m2 )b 23 (20-27) 25 (22-29) 0.026 
Daily insulin dose after stabilizationd (U/kg)b 0.41 (0.21-0.66) 0.36 (0.15-0.49) 0.195 
Initial classification as type 1 by treating physician [no. of 
patients (percent)] 
64/82 (78) 49/82 (60) 0.018 
Random C-peptidee(µg/liter) 1.12 (0.59-2.11) 1.65 (0.99-2.50) 0.009 
Amylasef(U/liter)b 50 (44-57) 47 (37-53) 0.050 
a Mann-Whitney U test was used for continuous variables and χ2 test for categorical variables; the threshold for 
statistical significance is P < 0.05/5 or P < 0.010 (Bonferroni adjustment). 
c Data were available for 67 patients with susceptible and 70 patients with protective/neutral genotypes. 
b Median (interquartile range). 
d Data were available for 58 patients with susceptible and 67 patients with protective/neutral genotypes. 
e Data were available for 81 patients with susceptible and 81 patients with protective/neutral genotypes. 
f Data were available for 80 patients with susceptible and 82 patients with protective/neutral genotypes. 
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DISCUSSION 
Adult-onset diabetes presents along a clinical spectrum ranging from acute ketosis-prone onset to latent forms 
diagnosed by the presence of chronic complications[1] [2] [3] [4] [5] M [7] [8] l9] . It is often difficult to classify patients 
at diagnosis solely on clinical grounds m [8] . Therefore, both disease classification and etiology-driven therapy 
would benefit from the optimal use of biological markers related to the underlying pathological process at 
diagnosis. 
In the present study, antibody-positive patients with primary diabetes diagnosed in adulthood were on average 
leaner and showed an earlier, more acute, and more severe clinical presentation, a less preserved β-cell mass, 
higher insulin requirements after stabilization, and a higher frequency of HLA-DQ and 5'INS risk genotypes than 
antibody-negative patients, in agreement with previous observations [4] [16] [17] m m [38] m . Both HLA-DQ risk 
genotypes and a more severe metabolic decompensation occur more frequently in childhood than in adult-onset 
immune-mediated diabetes [3] [10] [12] [25] m m . We therefore wondered whether the overall less severe clinical 
presentation in adult-onset type 1 diabetes was primarily associated with the lower prevalence of HLA-DQ risk 
markers or rather with older age at diagnosis per se. Hence, we investigated phenotype-genotype relations in 
antibody-positive and antibody-negative diabetic patients diagnosed in (early) adulthood. 
The presence of high-risk HLA-DQ genotypes is not a necessary condition for the development of immune-
mediated diabetes because 43% of the antibody-positive diabetic patients lacked such risk markers. The 
prevalence of the high-risk HLADR3/DR4 genotype in our population of childhood and adult-onset diabetic 
patients is similar to the prevalence reported in other studies [10] [12] [25][39] . Especially in the absence of 
susceptible HLA-DQ alleles, other genetic risk factors might be needed as suggested by the fact that the 
prevalence of the 5'INS I/I susceptibility genotype tended to be higher in antibody-positive subjects carrying 
neutral or protective HLA-DQ genotypes, as shown previously [30] . In the presence of autoantibodies, we 
observed no differences in clinical or biological characteristics according to HLA-DQ risk; this is at variance 
with earlier Scandinavian reports of a milder disease onset in HLA-DR3-positive type 1 patients [41] and of a 
more severe presentation in association with an increased HLA-DQB1 linked genetic risk load in diabetic 
children[42] . However, in these studies all patients were under age 20, and the different genotype groups had not 
been matched for age or antibody status, two important confounders. In line with our findings, a British study [39] 
concluded that the HLA-DQ genotype background may not have a major role in disease severity in terms of 
insulin requirements once autoimmunity has been established in adult-onset diabetes. 
In antibody-negative patients, HLA-DQ markers of immunemediated type 1 diabetes were overrepresented 
compared with the background population as reported previously [39] . Antibody-negative subjects displayed 
more type 1-like features in the presence of HLA-DQ risk than in their absence; they developed hyperglycemia 
at a younger age in the presence of genetic markers associated with earlier disease onset in immune-mediated 
type 1 diabetes [10] [11] [12], were leaner overall, and tended to have less preserved C-peptide levels and higher 
insulin needs. These trends persisted even after adjustment for age at diagnosis and during follow-up. Not 
surprisingly, antibody-negative patients were more frequently classified as having type 1 diabetes in the presence 
of HLA-DQ susceptibility genotypes than in their absence by physicians unaware of HLA and antibody status at 
that time. In carriers of HLA-DQ risk genotypes, the clinical and biological characteristics are suggesting the 
existence of an immune-mediated β-cell destructive process despite the absence of diabetes-associated 
autoantibodies. In insulin-dependent diabetes, antibodies indeed sometimes appear only months to years after 
diagnosis [22] [23]. It is conceivable that certain patients have seroconverted to antibody negativity in the 
preclinical phase or present other immune markers than those currently searched for[23] [43] [44] . On the basis of 
previous observations, it can be safely concluded that in the age categories studied there are very few, if any, 
recent-onset diabetic patients negative for the diabetes-associated autoantibodies measured in the present study 
(ICA, GADA, and IA-2A) but positive for IAA (<1%) [26] or for antibodies against a 38-kDa glycated islet cell 
membrane-associated protein (0%) [43] . At variance with a smaller study in Italian patients diagnosed in the age 
range 30-54 yr[38], but in line with the study of Pietropaolo et al. [45] , our results suggest that genetic risk markers 
known to promote the clinical onset of antibody -positive diabetes [1] [31] may indicate the presence of an 
immune-mediated disease process with yet unknown immune markers in patients with a type 1-like phenotype, 
but negative for the presently used antibody markers. 
A subgroup of Japanese insulinopenic antibody -negative patients with acute diabetes onset in adulthood, low 
HbAlc levels, and elevated serum activities of pancreatic enzymes at diagnosis has recently been described[19]. 
Neither the present large study nor preliminary reports [20] [21] [46] could document the frequent occurrence of this 
type of idiopathic type 1 diabetes in Caucasians. In our Belgian antibody-negative Caucasian patients, a more 
severe metabolic decompensation, higher insulin needs, and less preserved β-cell mass were associated with high 
Published in : Journal of Clinical Endocrinology and Metabolism (2002), vol.87, iss.6, pp. 2597-2605 
Status: Postprint (Author’s version) 
rather than low HbAlc levels, which is clearly discordant with the Japanese findings [19] but in line with a 
preliminary European report[20]. Furthermore, we did not identify subjects with elevated amylasemia or lipasemia 
among the subjects lacking genetic and antibody markers of immunemediated type 1 diabetes. Rather, amylase 
activity was lowest in antibody-negative subjects without HLA-DQ risk genotypes. It is unknown whether these 
lower amylase levels reflect increased enzyme clearance, decreased amylase synthesis due to relative acinar 
insulinopenia, or less leakage of enzymes from acinar cells [34]. 
We have observed a higher reported prevalence of familial diabetes in antibody-negative subjects compared with 
antibody-positive patients regardless of HLA-DQ genotype. It may be warranted to search for mutations 
associated with maturity onset diabetes of the young and mitochondrial diabetes because these inherited forms of 
diabetes are likely to be more prevalent in antibody-negative subjects with a familial history of diabetes and 
lacking HLA-DQ risk genotypes [44][47][48]. 
The present report confirms the marked male-over-female excess in adult-onset diabetes [14]. This excess tended 
to be more pronounced in antibody-negative patients compared with antibody -positive subjects. It is conceivable 
that in male subjects with already decreased β-cell function and/or mass increased BMI, a prominent risk factor 
for type 2 diabetes [7] , and the more visceral distribution of body fat may preferentially accelerate the clinical 
onset of diabetes as a consequence of higher metabolic demands due to increased insulin resistance [14]. 
Alternatively, one may wonder whether a higher BMI may (in part) reflect a better ability to (partially) restore β-
cell mass (and hence C-peptide and insulin levels) when confronted with ongoing β-cell destruction and/or 
peripheral insulin resistance [49]. In the light of a recent report on the association between the 5'INS I/I and 
juvenile obesity, we failed to detect a possible relation between BMI and 5'INS genotype[50]. 
In conclusion, antibody-positive adult-onset patients develop diabetes overall at a younger age and, regardless of 
HLA-DQ genotype, have a more severe clinical presentation at diagnosis than antibody-negative subjects. In the 
absence of autoantibodies, patients carrying HLA-DQ-linked risk have on average an earlier disease onset and, 
regardless of age, show more type 1-like features than subjects lacking HLA-DQ risk genotypes. Genetic risk 
markers of seropositive type 1 diabetes may thus indicate the existence of an immune-mediated disease process 
in patients lacking conventional diabetes autoantibodies. Idiopathic type 1 diabetes with acute onset and 
increased amylase activity is not a frequent phenotype in Caucasians. 
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